|Bid||87.39 x 100|
|Ask||87.41 x 400|
|Day's Range||86.62 - 87.61|
|52 Week Range||71.76 - 89.09|
|PE Ratio (TTM)||41.54|
|Forward Dividend & Yield||2.25 (2.56%)|
|1y Target Est||N/A|
This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.
Headquartered in New York City, pharmaceutical giant Bristol-Myers Squibb (BMY) offers various cardiovascular, immunoscience, neuroscience, oncology, and virology products.
Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.
The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]
Shares of Eli Lilly (LLY) are climbing on Wednesday, after the drug maker's updated guidance for this year and next. Eli Lilly said that it expects to earn between $4.15 and $4.25 a share for fiscal 2017, on revenues of $22.4 billion to $22.7 billion. For fiscal 2018, Eli Lilly said it expects to earn between $4.60 and $4.70 a share, on revenue of $23 billion to $23.5 billion.
Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz. Lilly said it was expecting a regulatory decision on its rheumatoid arthritis drug baricitinib, whose marketing application was initially rejected by the U.S. Food and Drug Administration. The drugmaker also expects to launch a new indication for Taltz in psoriatic arthritis.
In 3Q17, Eli Lilly's (LLY) Olumiant (baricitinib) reported revenues of $16.2 million compared to $4.8 million and $1.9 million in 2Q17 and 1Q17, respectively.
In 3Q17, Eli Lilly’s (LLY) Animal Health segment reported revenues of $740.6 million, a ~5% increase on a year-over-year (or YoY) basis and a 6% decline on a quarter-over-quarter basis.
Eli Lilly and Co. said Monday its board approved an 8% hike in its quarterly dividend. The drugmaker said it will pay a 56.25 cents a share dividend in the first quarter to shareholders of record as of ...
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.
The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...
In 3Q17, Eli Lilly's (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.
In 3Q17, Eli Lilly's (LLY) Cyramza generated revenues of $196 million, which reflected ~23% growth on a YoY basis and 5% growth on a quarter-over-quarter basis.
Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates. The company said it would not seek a regulatory approval based on the results. The study tested Cyramza in combination with other drugs as a first-line treatment for patients with advanced forms of gastric cancer, which is estimated to result in the deaths of nearly 11,000 people in the United States this year.
Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a treatment for a type of gastric cancer met its main goal of preventing the disease from advancing. However the trial failed ...
In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.